{"id":58929,"date":"2026-03-06T15:43:33","date_gmt":"2026-03-06T07:43:33","guid":{"rendered":"https:\/\/flcube.com\/?p=58929"},"modified":"2026-03-06T15:43:34","modified_gmt":"2026-03-06T07:43:34","slug":"jjs-tecvayli-wins-fda-approval-in-earlier-line-myeloma-bcma-bite-plus-daratumumab-combo-expands-addressable-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58929","title":{"rendered":"J&amp;J&#8217;s TECVAYLI Wins FDA Approval in Earlier-Line Myeloma \u2013 BCMA BiTE Plus Daratumumab Combo Expands Addressable Market"},"content":{"rendered":"\n<p><strong>Johnson &amp; Johnson<\/strong> (J&amp;J, <a href=\"https:\/\/www.google.com\/finance\/quote\/JNJ:NYSE\">NYSE: JNJ<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has approved <strong>TECVAYLI (teclistamab)<\/strong> in <strong>combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)<\/strong> for the treatment of <strong>adult patients with relapsed or refractory multiple myeloma (RRMM)<\/strong> who have received <strong>at least one prior line of therapy<\/strong> (including a proteasome inhibitor and an immunomodulatory agent). The approval expands TECVAYLI&#8217;s indication from fourth-line to <strong>second-line setting<\/strong>, significantly broadening its commercial opportunity in the $22 billion multiple myeloma market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Label expansion (new combination, earlier line of therapy)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>TECVAYLI (teclistamab) + DARZALEX FASPRO (daratumumab\/hyaluronidase)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Relapsed or refractory multiple myeloma (RRMM)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adults with \u22651 prior therapy (PI + IMiD exposure required)<\/td><\/tr><tr><td><strong>Prior Approvals<\/strong><\/td><td>EU (2022), U.S. (2022, 4L+), China (June 2024)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>5\u202fMar\u202f2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Commercial launch; formulary negotiations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<p><strong>TECVAYLI (Teclistamab):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> First-in-class bispecific T-cell engager (BiTE) antibody<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Dual binding to <strong>CD3<\/strong> (T-cell surface) and <strong>BCMA<\/strong> (B-cell maturation antigen on myeloma cells)<\/li>\n\n\n\n<li><strong>Action:<\/strong> Redirects patient T-cells to target and eliminate BCMA-expressing myeloma cells<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Subcutaneous injection (off-the-shelf, no CAR-T manufacturing required)<\/li>\n<\/ul>\n\n\n\n<p><strong>DARZALEX FASPRO:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Component:<\/strong> Daratumumab (anti-CD38 monoclonal antibody) + hyaluronidase-fihj (enhanced subcutaneous delivery)<\/li>\n\n\n\n<li><strong>Role in Combo:<\/strong> Dual myeloma targeting (BCMA + CD38) with complementary immune mechanisms<\/li>\n<\/ul>\n\n\n\n<p><strong>Synergy Rationale:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>BiTE-mediated T-cell activation + anti-CD38 antibody-dependent cellular cytotoxicity<\/li>\n\n\n\n<li>Subcutaneous administration for both agents enables outpatient treatment<\/li>\n\n\n\n<li>Reduced treatment burden vs. CAR-T or bispecific monotherapy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-amp-commercial-impact\">Clinical &amp; Commercial Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Strategic Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Line of Therapy<\/strong><\/td><td>Moves from 4L+ to 2L+ \u2014 <strong>3x addressable patient expansion<\/strong><\/td><\/tr><tr><td><strong>Market Timing<\/strong><\/td><td>Competes directly with CAR-T therapies (cilta-cel, ide-cel) in earlier relapse setting<\/td><\/tr><tr><td><strong>Convenience Advantage<\/strong><\/td><td>Off-the-shelf subcutaneous vs. CAR-T manufacturing\/logistics complexity<\/td><\/tr><tr><td><strong>Revenue Forecast<\/strong><\/td><td>Analysts project <strong>$3\u20135 billion peak sales<\/strong> for TECVAYLI franchise with this expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Positioning<\/th><th>TECVAYLI Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>J&amp;J<\/strong><\/td><td>CARVYKTI (cilta-cel)<\/td><td>2L+ CAR-T<\/td><td>TECVAYLI offers outpatient, no lymphodepletion<\/td><\/tr><tr><td><strong>BMS<\/strong><\/td><td>Abecma (ide-cel)<\/td><td>2L+ CAR-T<\/td><td>Faster time-to-treatment, broader site availability<\/td><\/tr><tr><td><strong>Pfizer<\/strong><\/td><td>ELREXFIO (elranatamab)<\/td><td>2L+ BiTE<\/td><td>First-mover advantage; daratumumab combo unique<\/td><\/tr><tr><td><strong>Regeneron<\/strong><\/td><td>LINVOSITY (linvoseltamab)<\/td><td>2L+ BiTE<\/td><td>J&amp;J&#8217;s Darzalex integration creates combo barrier<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-commercial-strategy\">Global Commercial Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>U.S. Launch:<\/strong> Immediate availability; J&amp;J&#8217;s oncology sales force (2,000+ reps) deployed<\/li>\n\n\n\n<li><strong>Pricing Power:<\/strong> Combo premium justified by Phase III MajesTEC-3 data showing superior PFS vs. standard of care<\/li>\n\n\n\n<li><strong>International Expansion:<\/strong> EU label update filing Q2 2026; China indication expansion under NMPA review<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial projections, competitive positioning, and regulatory expansion for TECVAYLI. Actual results may differ due to pricing negotiations, competitive dynamics, and reimbursement decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58934,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,150,149,858,15],"class_list":["post-58929","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-jj","tag-johnson-johnson","tag-nyse-jnj","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>J&amp;J&#039;s TECVAYLI Wins FDA Approval in Earlier-Line Myeloma \u2013 BCMA BiTE Plus Daratumumab Combo Expands Addressable Market - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has approved TECVAYLI (teclistamab) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy (including a proteasome inhibitor and an immunomodulatory agent). The approval expands TECVAYLI&#039;s indication from fourth-line to second-line setting, significantly broadening its commercial opportunity in the $22 billion multiple myeloma market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58929\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"J&amp;J&#039;s TECVAYLI Wins FDA Approval in Earlier-Line Myeloma \u2013 BCMA BiTE Plus Daratumumab Combo Expands Addressable Market\" \/>\n<meta property=\"og:description\" content=\"Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has approved TECVAYLI (teclistamab) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy (including a proteasome inhibitor and an immunomodulatory agent). The approval expands TECVAYLI&#039;s indication from fourth-line to second-line setting, significantly broadening its commercial opportunity in the $22 billion multiple myeloma market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58929\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-06T07:43:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-06T07:43:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0604.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58929#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58929\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"J&amp;J&#8217;s TECVAYLI Wins FDA Approval in Earlier-Line Myeloma \u2013 BCMA BiTE Plus Daratumumab Combo Expands Addressable Market\",\"datePublished\":\"2026-03-06T07:43:33+00:00\",\"dateModified\":\"2026-03-06T07:43:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58929\"},\"wordCount\":450,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58929#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0604.webp\",\"keywords\":[\"Cancer\",\"J&amp;J\",\"Johnson &amp; Johnson\",\"NYSE: JNJ\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58929#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58929\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58929\",\"name\":\"J&amp;J's TECVAYLI Wins FDA Approval in Earlier-Line Myeloma \u2013 BCMA BiTE Plus Daratumumab Combo Expands Addressable Market - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58929#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58929#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0604.webp\",\"datePublished\":\"2026-03-06T07:43:33+00:00\",\"dateModified\":\"2026-03-06T07:43:34+00:00\",\"description\":\"Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has approved TECVAYLI (teclistamab) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy (including a proteasome inhibitor and an immunomodulatory agent). The approval expands TECVAYLI's indication from fourth-line to second-line setting, significantly broadening its commercial opportunity in the $22 billion multiple myeloma market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58929#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58929\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58929#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0604.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0604.webp\",\"width\":1080,\"height\":608,\"caption\":\"J&J's TECVAYLI Wins FDA Approval in Earlier-Line Myeloma \u2013 BCMA BiTE Plus Daratumumab Combo Expands Addressable Market\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58929#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"J&amp;J&#8217;s TECVAYLI Wins FDA Approval in Earlier-Line Myeloma \u2013 BCMA BiTE Plus Daratumumab Combo Expands Addressable Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"J&amp;J's TECVAYLI Wins FDA Approval in Earlier-Line Myeloma \u2013 BCMA BiTE Plus Daratumumab Combo Expands Addressable Market - Insight, China&#039;s Pharmaceutical Industry","description":"Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has approved TECVAYLI (teclistamab) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy (including a proteasome inhibitor and an immunomodulatory agent). The approval expands TECVAYLI's indication from fourth-line to second-line setting, significantly broadening its commercial opportunity in the $22 billion multiple myeloma market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58929","og_locale":"en_US","og_type":"article","og_title":"J&amp;J's TECVAYLI Wins FDA Approval in Earlier-Line Myeloma \u2013 BCMA BiTE Plus Daratumumab Combo Expands Addressable Market","og_description":"Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has approved TECVAYLI (teclistamab) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy (including a proteasome inhibitor and an immunomodulatory agent). The approval expands TECVAYLI's indication from fourth-line to second-line setting, significantly broadening its commercial opportunity in the $22 billion multiple myeloma market.","og_url":"https:\/\/flcube.com\/?p=58929","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-06T07:43:33+00:00","article_modified_time":"2026-03-06T07:43:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0604.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58929#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58929"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"J&amp;J&#8217;s TECVAYLI Wins FDA Approval in Earlier-Line Myeloma \u2013 BCMA BiTE Plus Daratumumab Combo Expands Addressable Market","datePublished":"2026-03-06T07:43:33+00:00","dateModified":"2026-03-06T07:43:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58929"},"wordCount":450,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58929#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0604.webp","keywords":["Cancer","J&amp;J","Johnson &amp; Johnson","NYSE: JNJ","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58929#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58929","url":"https:\/\/flcube.com\/?p=58929","name":"J&amp;J's TECVAYLI Wins FDA Approval in Earlier-Line Myeloma \u2013 BCMA BiTE Plus Daratumumab Combo Expands Addressable Market - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58929#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58929#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0604.webp","datePublished":"2026-03-06T07:43:33+00:00","dateModified":"2026-03-06T07:43:34+00:00","description":"Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has approved TECVAYLI (teclistamab) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy (including a proteasome inhibitor and an immunomodulatory agent). The approval expands TECVAYLI's indication from fourth-line to second-line setting, significantly broadening its commercial opportunity in the $22 billion multiple myeloma market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58929#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58929"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58929#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0604.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0604.webp","width":1080,"height":608,"caption":"J&J's TECVAYLI Wins FDA Approval in Earlier-Line Myeloma \u2013 BCMA BiTE Plus Daratumumab Combo Expands Addressable Market"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58929#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"J&amp;J&#8217;s TECVAYLI Wins FDA Approval in Earlier-Line Myeloma \u2013 BCMA BiTE Plus Daratumumab Combo Expands Addressable Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0604.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58929","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58929"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58929\/revisions"}],"predecessor-version":[{"id":58935,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58929\/revisions\/58935"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58934"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58929"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58929"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58929"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}